These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 35788169)

  • 21. ChemoPROphyLaxIs with hydroxychloroquine For covId-19 infeCtious disease (PROLIFIC) to prevent covid-19 infection in frontline healthcare workers: A structured summary of a study protocol for a randomised controlled trial.
    McEniery CM; Fisk M; Miles K; Kaloyirou F; Hubsch A; Smith J; Wilkinson IB; Cheriyan J
    Trials; 2020 Jul; 21(1):604. PubMed ID: 32616067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pre-exposure prophylaxis with hydroxychloroquine for high-risk healthcare workers during the COVID-19 pandemic: A structured summary of a study protocol for a multicentre, double-blind randomized controlled trial.
    Grau-Pujol B; Camprubí D; Marti-Soler H; Fernández-Pardos M; Guinovart C; Muñoz J
    Trials; 2020 Jul; 21(1):688. PubMed ID: 32727613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of oral ivermectin in the treatment of mild to moderate Covid-19 patients: a multi-centre double-blind randomized controlled clinical trial.
    Wijewickrema A; Banneheke H; Pathmeswaran A; Refai FW; Kauranaratne M; Malavige N; Jeewandara C; Ekanayake M; Samaraweera D; Thambavita D; Galappatthy P
    BMC Infect Dis; 2024 Jul; 24(1):719. PubMed ID: 39039459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand.
    Mikamo H; Takahashi S; Yamagishi Y; Hirakawa A; Harada T; Nagashima H; Noguchi C; Masuko K; Maekawa H; Kashii T; Ohbayashi H; Hosokawa S; Maejima K; Yamato M; Manosuthi W; Paiboonpol S; Suganami H; Tanigawa R; Kawamura H;
    J Infect Chemother; 2024 Jun; 30(6):536-543. PubMed ID: 38154616
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial.
    Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM;
    Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of antiviral combination therapy in symptomatic patients of Covid-19 infection - a randomised controlled trial (SEV-COVID Trial): A structured summary of a study protocol for a randomized controlled trial.
    Panda PK; Bandyopadhyay A; Singh BC; Moirangthem B; Chikara G; Saha S; Bahurupi YA
    Trials; 2020 Oct; 21(1):866. PubMed ID: 33081849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.
    Dubée V; Roy PM; Vielle B; Parot-Schinkel E; Blanchet O; Darsonval A; Lefeuvre C; Abbara C; Boucher S; Devaud E; Robineau O; Rispal P; Guimard T; d'Anglejean E; Diamantis S; Custaud MA; Pellier I; Mercat A; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
    Clin Microbiol Infect; 2021 Aug; 27(8):1124-1130. PubMed ID: 33813110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial.
    Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Medina MF; Achinelli F; Guglielmone HA; Ojeda J; Farizano Salazar D; Andino G; Kawerin P; Dellamea S; Aquino AC; Flores V; Martemucci CN; Martinez SM; Segovia JE; Reynoso PI; Sosa NC; Robledo ME; Guarrochena JM; Vernengo MM; Ruiz Diaz N; Meza E; Aguirre MG
    BMC Infect Dis; 2021 Jul; 21(1):635. PubMed ID: 34215210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
    Nanni O; Viale P; Vertogen B; Lilli C; Zingaretti C; Donati C; Masini C; Monti M; Serra P; Vespignani R; Grossi V; Biggeri A; Scarpi E; Galardi F; Bertoni L; Colamartini A; Falcini F; Altini M; Massa I; Gaggeri R; Martinelli G
    Trials; 2020 Jul; 21(1):689. PubMed ID: 32736597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of single-dose and double-dose ivermectin early treatment in preventing progression to hospitalization in mild COVID-19: A multi-arm, parallel-group randomized, double-blind, placebo-controlled trial.
    Mirahmadizadeh A; Semati A; Heiran A; Ebrahimi M; Hemmati A; Karimi M; Basir S; Zare M; Charlys da Costa A; Zeinali M; Sargolzaee M; Eilami O
    Respirology; 2022 Sep; 27(9):758-766. PubMed ID: 35738778
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
    Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
    Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-COVID property of subcutaneous ivermectin in synergy with zinc among midlife moderately symptomatic patients: a structured summary of a study protocol for a randomised controlled trial.
    Ashraf S; Ashraf S; Farooq I; Ashraf S; Ashraf M; Imran MA; Kalsoom L; Akmal R; Ghufran M; Rafique S; Akram MK; Habib Z; Siddiqui UN; Ahmad A; Arshad S; Virk MAR; Gul M; Awais AB; Hassan M; Sherazi SSH; Safdar Z; Munir I; Khalid H; Munir K; Majeed N; Alahmadi YM; Humayun A; Saboor QA; Ahmad A; Ashraf M; Izhar M;
    Trials; 2021 Sep; 22(1):591. PubMed ID: 34488858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes associated with Hydroxychloroquine and Ivermectin in hospitalized patients with COVID-19: a single-center experience.
    Ferreira RM; Beranger RW; Sampaio PPN; Mansur Filho J; Lima RAC
    Rev Assoc Med Bras (1992); 2021 Oct; 67(10):1466-1471. PubMed ID: 35018977
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of hydroxychloroquine for treatment of mild SARS-CoV-2 infection and prevention of COVID-19 severity in pregnant and postpartum women: A randomized, double-blind, placebo-controlled trial.
    González R; Goncé A; Gil MDM; Mazarico E; Ferriols-Pérez E; Toro P; Llurba E; Saéz E; Rodríguez-Zambrano MÁ; García-Otero L; López M; Santacruz B; Román MÁ; Payà A; Alonso S; Cruz-Lemini M; Pons-Duran C; Herrera LB; Chen H; Bardají A; Quintó L; Menendez C;
    Acta Obstet Gynecol Scand; 2024 Mar; 103(3):602-610. PubMed ID: 38098221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
    López-Medina E; López P; Hurtado IC; Dávalos DM; Ramirez O; Martínez E; Díazgranados JA; Oñate JM; Chavarriaga H; Herrera S; Parra B; Libreros G; Jaramillo R; Avendaño AC; Toro DF; Torres M; Lesmes MC; Rios CA; Caicedo I
    JAMA; 2021 Apr; 325(14):1426-1435. PubMed ID: 33662102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
    Reis G; Moreira Silva EADS; Medeiros Silva DC; Thabane L; Singh G; Park JJH; Forrest JI; Harari O; Quirino Dos Santos CV; Guimarães de Almeida APF; Figueiredo Neto AD; Savassi LCM; Milagres AC; Teixeira MM; Simplicio MIC; Ribeiro LB; Oliveira R; Mills EJ;
    JAMA Netw Open; 2021 Apr; 4(4):e216468. PubMed ID: 33885775
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Early Treatment with Ivermectin among Patients with Covid-19.
    Reis G; Silva EASM; Silva DCM; Thabane L; Milagres AC; Ferreira TS; Dos Santos CVQ; Campos VHS; Nogueira AMR; de Almeida APFG; Callegari ED; Neto ADF; Savassi LCM; Simplicio MIC; Ribeiro LB; Oliveira R; Harari O; Forrest JI; Ruton H; Sprague S; McKay P; Guo CM; Rowland-Yeo K; Guyatt GH; Boulware DR; Rayner CR; Mills EJ;
    N Engl J Med; 2022 May; 386(18):1721-1731. PubMed ID: 35353979
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.